摘要
目的探究免疫学指标、炎性因子联合临床特征预测卵巢癌患者预后的价值。方法回顾性分析2018年3月—2019年3月收治的卵巢癌134例的临床资料,根据随访2年内是否发生死亡将患者分为预后不良组32例和预后良好组102例。收集2组入院时临床资料。测定2组CD4+、CD8+、CD4+/CD8+、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平。采用多因素Logistic回归分析卵巢癌患者预后不良的影响因素。结果年龄≥60岁、病理分期Ⅲ~Ⅳ期、低分化、CD4+<35%、CD8+≥32%、CD4+/CD8+<1.1、IL-6≥24 mg/L、TNF-α≥28 mg/L、CRP≥21 mg/L是卵巢癌患者预后不良的独立影响因素(P<0.01)。结论年龄、病理分期、组织学分级、免疫学指标、炎性因子水平与卵巢癌患者预后情况密切相关。
Objective To explore values of immunological indexes,inflammatory factors combined with clinical characteristics in prediction of prognoses of patients with ovarian cancer.Methods Clinical data of 134 patients with ovarian cancer admitted between March 2018 and March 2019 was retrospectively analyzed,and the patients were divided into poor prognosis group(n=32)and good prognosis group(n=102)according to presence or absence of death within 2 years of follow-up.Clinical data of patients in two groups at admission was collected.Levels of CD4+,CD8+,CD4+/CD8+,interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)and C-reactive protein(CRP)were detected in two groups.Multivariate Logistic regression analysis was performed to clarify influencing factors of poor prognoses of patients with ovarian cancer.Results Age equal or more than 60 years old,pathological stagingⅢ-Ⅳ,low differentiation,CD4+less than 35%,CD8+equal or more than 32%,CD4+/CD8+less than 1.1,IL-6 equal or more than 24 mg/L,TNF-αequal or more than 28 mg/L and CRP equal or more than 21 mg/L were independent influencing factors of poor prognoses of patients with ovarian cancer(P<0.01).Conclusion Age,pathological staging,histological grade,immunological indexes and levels of inflammatory factors are closely related to prognoses of patients with ovarian cancer.
作者
崔娇姣
周鹏翔
高翠红
CUI Jiao-jiao;ZHOU Peng-xiang;GAO Cui-hong(Department of Clinical Laboratory,Maternal and Child Health Hospital of Tangshan City,Tangshan,Hebei 063000,China;Department of Clinical Laboratory,Tangshan Workers'Hospital,Tangshan,Hebei 063000,China)
出处
《解放军医药杂志》
CAS
2022年第4期22-24,27,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
河北省医学科学研究重点课题计划项目(20191531)。
